HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
Authors:
- Paul M RidkerPRPaul M Ridker
- Jacques GenestJGJacques Genest
- S Matthijs BoekholdtSBS Matthijs Boekholdt
- Peter LibbyPLPeter Libby
- Antonio M GottoAGAntonio M Gotto
- Børge G NordestgaardBNBørge G Nordestgaard
- Samia MoraSMSamia Mora
- Jean G MacFadyenJMJean G MacFadyen
- Robert J GlynnRGRobert J Glynn
- John Jp KasteleinJKJohn Jp Kastelein
- 1 July 2010
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 376 (9738) , 333-339
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 24 references indexed in Scilit:
- A Randomized Trial of Rosuvastatin in the Prevention of Venous ThromboembolismNew England Journal of Medicine, 2009
- Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary SyndromesArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Metabolic and physiologic improvements from consuming a paleolithic, hunter-gatherer type dietEuropean Journal of Clinical Nutrition, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Beyond High-Density Lipoprotein Cholesterol LevelsJACC, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- Effect of Torcetrapib on Carotid Atherosclerosis in Familial HypercholesterolemiaNew England Journal of Medicine, 2007
- Effect of Torcetrapib on the Progression of Coronary AtherosclerosisNew England Journal of Medicine, 2007
- The Failure of TorcetrapibArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002